Indications and uses
Neuralgo-Rheum® Injection Solution is a homeopathic drug product indicated for the treatment of nerve pain, soft tissue rheumatism and symptoms of disc protrusion.
Neuralgo-Rheum® Injection Solution is a homeopathic drug product indicated for the treatment of nerve pain, soft tissue rheumatism and symptoms of disc protrusion.
General Considerations The dosage schedules listed below can be used as a general guide for the administration of Neuralgo-Rheum Injection Solution. • Neuralgo-Rheum Injection Solution may be administered s.c., i.d., i.m., or i.v.. • If co-administration with a local anesthetic is desired, Neuralgo-Rheum Injection Solution may be mixed with lidocaine or similar agents at the discretion of the physician. • The int...
| Each 1.1 ml solution for injection ampule contains: | |||
| Active Ingredients: | |||
| Ingredient name | Potency | Quantity | Final dilution |
| Causticum | 10X | 1.1 µl | 12.99 |
| Causticum | 30X | 1.1 µl | 32.99 |
| Causticum | 200X | 1.1 µl | 203.00 |
| Colchicum autumnale | 10X | 1.1 µl | 12.99 |
| Colchicum autumnale | 30X | 1.1 µl | 32.99 |
| Colchicum autumnale | 200X | 1.1 µl | 203.00 |
| Colocynthis | 10X | 1.1 µl | 12.99 |
| Colocynthis | 30X | 1.1 µl | 32.99 |
| Ferrum metallicum | 10X | 1.1 µl | 12.99 |
| Ferrum metallicum | 30X | 1.1 µl | 32.99 |
| Gnaphalium polycephalum | 6X | 3.3 µl | 8.52 |
| Gnaphalium polycephalum | 10X | 3.3 µl | 12.52 |
| Gnaphalium polycephalum | 30X | 3.3 µl | 32.52 |
| Lithium benzoicum | 10X | 1.1 µl | 12.99 |
| Lithium benzoicum | 30X | 1.1 µl | 32.99 |
| Rhus toxicodendron | 10X | 1.1 µl | 12.99 |
| Rhus toxicodendron | 30X | 1.1 µl | 32.99 |
| Spiraea ulmaria | 10X | 1.1 µl | 12.99 |
| Spiraea ulmaria | 30X | 1.1 µl | 32.99 |
List of Excipients:
Water for injection 1,072.5 μl
Sodium Chloride 10.3 μl
Neuralgo-Rheum® Injection Solution is a homeopathic drug product indicated for the treatment of nerve pain, soft tissue rheumatism and symptoms of disc protrusion.
General Considerations
The dosage schedules listed below can be used as a general guide for the administration of Neuralgo-Rheum Injection Solution.
• Neuralgo-Rheum Injection Solution may be administered s.c., i.d., i.m., or i.v..
• If co-administration with a local anesthetic is desired, Neuralgo-Rheum Injection Solution may be mixed with lidocaine or similar agents at the discretion of the physician.
• The interval between injections is left to the discretion of the HCP, but should not exceed 1 ampule in 24 hours.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
• Draw up required dose into syringe.
• Discard any unused ampule contents. Do not reuse ampule.
• Only licensed practitioners with sufficient expertise in injecting drugs, including the respective route of administration, should administer the product.
Standard Dosage:
Adults and children 12 years and older: 1 ml 1 to 3 times per 7 days.
Children 6 to 11 years: 0.7 ml 1 to 3 times per 7 days.
Children 2 to 5 years: 0.5 ml 1 to 3 times per 7 days.
Acute Dosage:
Adults and children 12 years and older: 1 ml daily, and then continue with standard dosage.
Children 6 to 11 years: 0.7 ml daily, and then continue with standard dosage.
Children 2 to 5 years: 0.5 ml daily, and then continue with standard dosage.
Neuralgo-Rheum Injection Solution is contraindicated in patients with known hypersensitivity to Neuralgo-Rheum or any of its ingredients.
None
No negative effects of an overdose have been reported and none are expected due to the homeopathic dilutions.
Mechanism of Action
The exact mechanism of Neuralgo-Rheum Injection Solution is not fully understood.
Pharmacodynamics
Not applicable for homeopathic medicinal products.
1 ampule containing 1.1 ml solution for injection each containing the active ingredients in the strengths listed under Description.
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50114-7070-1 | ML - Milliliter | 50114-7070 | 19e869d5-07fb-4de8-a5fa-b0d9f5b59f16 | 1 | 2015-10-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAUSTICUM | ACTIVE INGREDIENT | DD5FO1WKFU | 4 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE INGREDIENT | 23H32AOH17 | 4 | |
| COLCHICUM AUTUMNALE BULB | ACTIVE INGREDIENT | 993QHL78E6 | 4 | |
| FILIPENDULA ULMARIA ROOT | ACTIVE INGREDIENT | 997724QNDS | 4 | |
| IRON | ACTIVE INGREDIENT | E1UOL152H7 | 4 | |
| LITHIUM BENZOATE | ACTIVE INGREDIENT | R9Z042Z19E | 4 | |
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | ACTIVE INGREDIENT | 36XQ854NWW | 4 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 4 | |
| CAUSTICUM | ACTIVE MOIETY | DD5FO1WKFU | 4 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE MOIETY | 23H32AOH17 | 4 | |
| COLCHICUM AUTUMNALE BULB | ACTIVE MOIETY | 993QHL78E6 | 4 | |
| FILIPENDULA ULMARIA ROOT | ACTIVE MOIETY | 997724QNDS | 4 | |
| IRON | ACTIVE MOIETY | E1UOL152H7 | 4 | |
| LITHIUM CATION | ACTIVE MOIETY | 8H8Z5UER66 | 4 | |
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | ACTIVE MOIETY | 36XQ854NWW | 4 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 4 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50114-7070 | 50114-7070-1, 50114-7070-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| PSEUDOGNAPHALIUM OBTUSIFOLIUM | 36XQ854NWW | ACTIB |
| CAUSTICUM | DD5FO1WKFU | ACTIB |
| COLCHICUM AUTUMNALE BULB | 993QHL78E6 | ACTIB |
| CITRULLUS COLOCYNTHIS FRUIT PULP | 23H32AOH17 | ACTIB |
| IRON | E1UOL152H7 | ACTIB |
| LITHIUM BENZOATE | R9Z042Z19E | ACTIB |
| TOXICODENDRON PUBESCENS LEAF | 6IO182RP7A | ACTIB |
| FILIPENDULA ULMARIA ROOT | 997724QNDS | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GRANULE, FOR SUSPENSION / ORAL | 162 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, EXTENDED RELEASE / ORAL | 335.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / OPHTHALMIC | 55 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / TOPICAL | 0.32 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CREAM / TOPICAL | 0.4 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / NASAL | 330 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVITREAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ENDOTRACHEAL | 7.6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVENOUS | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2922 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / RETROBULBAR | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERINEURAL | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRASYNOVIAL | 4 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAOCULAR | 320 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / RESPIRATORY (INHALATION) | 108 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION, LIPOSOMAL / EPIDURAL | 11 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRATHECAL | 131 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / VAGINAL | 10 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVESICAL | 351 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SHAMPOO / TOPICAL | 150 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBCUTANEOUS | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVENOUS | 2916 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / TOPICAL | 210 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, EMULSION / INTRAVENOUS | 0.62 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / PARENTERAL | 210 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / EPIDURAL | 3535 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER / TOPICAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 226 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / RECTAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOAP / TOPICAL | 1.26 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / DENTAL | 0.4 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAMUSCULAR | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INFILTRATION | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY, METERED / NASAL | 36 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | IMPLANT / SUBCUTANEOUS | 77 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAPERITONEAL | 0.54 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, COATED / ORAL | 54.7 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 77406bbb-5db0-4ff7-bc6a-559e0456cd59 | fa2a3546-29df-4f74-bd14-95fa0753e9b0 | 2021-10-14 | Warnings, Adverse reactions | 77406bbb-5db0-4ff7-bc6a-559e0456cd59 fa2a3546-29df-4f74-bd14-95fa0753e9b0 |
Adverse event summaries are temporarily unavailable. Other product information remains available.